The CFF announced yesterday up to a $58 M investment in pre-clinical research to Pfizer over the next six years for correctors aimed at df508. Looks like Pfizer got into the arena by buying FoldRX. Looking for some insights:
1) Anyone know what FoldRX had on its plate re correctors?
2) Are there multiple high-thoroughput mechanisms for screening small molecules? In other words, wil Pfizer and Vertex be screening using the same or different methods?
3) Do different pharmas "own" or have "access" to different molecules, such that Pfizer could be testing different ones or would they both be looking at the same universe of molecules.
4) Any thoughts on the timing? CFF indicated goal at end of 6 years was to be in clinical studies. Could it be faster?
5) What else am I missing?
not sure what preclinical models they use for CF. someone else in that area might know. any pharma company can make a molecule they want as long as it's not in some patent space that someone else owns.